Hospitals are easing the cancer battles of young patients

February 12, 2013 by Alan Bavley, The Kansas City Star

It's been a weekly routine for years at the Jolley household in Independence, Mo. - crushing chemotherapy pills and mixing them with fruit juice so that 6-year-old Trevor, who is under treatment for leukemia, can gulp them down.

"I think almost all of us who have children with have to deal with crushing pills," said Trevor's mother, Amy Jolley. "Parents are crushing chemo pills on the kitchen counter."

The reason: Many cancer drugs were developed with adult patients in mind, and a lot are in pills that young children find hard to swallow.

That situation may be about to change.

Researchers at Children's Mercy Hospital and the University of Kansas Medical Center are reformulating drugs into liquids that are easy to swallow - and not bad-tasting, either.

"It's sweet, nondescript, not quite cherry-flavor," Kathleen Neville, a cancer researcher at Children's Mercy, said of a liquid version of a mainstay cancer drug that may soon be tried on patients.

Neville, along with Amy and Trevor Jolley, were part of a presentation last week at Children's Mercy to showcase cancer research collaborations between the hospital and other research centers.

Cancer research in Kansas City has been in expansion mode, largely the result of the university's efforts to gain designation as a National Cancer Institute cancer center; it received the designation last summer and already is preparing to apply in 2016 for the 's higher designation as a comprehensive cancer center. That will demand an even more extensive research portfolio.

Among the cancer research projects Children's Mercy has under way:

-Modifying the immune system of patients to focus on neuroblastoma, an often deadly cancer of , and melanoma, a dangerous form of .

-Processing the blood of with a chemical treatment and exposure to ultraviolet light to prevent complications from stem-cell transplants the patients received.

-Studying the biology of leukemia cells containing a genetic mutation that makes the disease very difficult to cure even with the most aggressive treatment.

And Neville is working with researchers at the University of Kansas Cancer Center's drug discovery program to develop a liquid version of 6-mercaptopurine, 6-MP, a drug essential for fighting childhood leukemia and other conditions.

"It's the very backbone of treatment," Neville said.

The drug has been around for about 50 years, but only as a tablet. Pharmacists can crush and mix 6-MP into a liquid for large medical centers such as Children's Mercy that have access to a compounding pharmacy to customize drugs. But this service isn't available at every hospital, and mixing 6-MP this way "is not an exact science," Neville said.

Neville said the market for a standardized liquid version of 6-MP is too small to interest drug companies in investing in its development.

"There is no incentive for big pharma to take this one, so it's up to the academic community," she said.

Children won't be the only patients to benefit, Neville said. A liquid 6-MP also may be prescribed to the elderly and others who have difficulty swallowing.

On Tuesday, Neville took her preliminary research data to the Food and Drug Administration.

"There's still some fine-tuning of the formulation," she said.

Neville expects a definitive clinical trial of the final version of the drug in the near future. FDA approval may be about five years off.

"In the drug development world that's a blink of an eye," Neville said.

Neville already is planning to work with the school's researchers on "pediatric-friendly" reformulations of other .

"There's a list that long," she said, stretching her hands far apart. "So stay tuned."

Explore further: FDA clears Pfizer drug for advanced kidney cancer

shares

Related Stories

FDA clears Pfizer drug for advanced kidney cancer

January 27, 2012
(AP) -- The Food and Drug Administration has approved a new Pfizer drug for patients with advanced kidney cancer that has spread to other parts of the body despite treatment with at least one previous drug.

Gleevec's latest approval is for pediatric cancer

January 25, 2013
(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said ...

FDA panel backs Pfizer drug for kidney cancer

December 7, 2011
(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.

Key to fighting drug-resistant leukemia found

May 18, 2011
Doctors who treat children with the most common form of childhood cancer – acute lymphoblastic leukemia – are often baffled at how sometimes the cancer cells survive their best efforts and the most powerful modern ...

Scientists develop new strategy to overcome drug-resistant childhood cancer

July 11, 2012
A new drug combination could offer hope to children with neuroblastoma – one of the deadliest forms of childhood cancer – by boosting the effectiveness of a promising new gene-targeted treatment.

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.